The Food and Drug Administration yesterday updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients.

The document includes information on the changes to Gilead’s fact sheets for health care providers and patient caregivers.

FDA this week also posted a patient-and-consumer-focused FAQ about SARS-CoV-2 antibody, or serology, testing, including a guide to understanding test results and where to obtain them.

Related News Articles

Headline
The AHA’s American Organization of Nursing Leadership affiliate, the American Nurses Association, and Johnson & Johnson this week released a report…
Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
Throughout the COVID-19 pandemic, Sutter Health in Northern California used the range of its system to meet the needs of patients, staff and clinicians, from…
Headline
U.S. life expectancy fell by an average of 1.5 years in 2020 to 77.3 years, primarily due to COVID-19, the Centers for Disease Control and Prevention reported…